Outlook Therapeutics Relocates HQ, Reports Officer/Director Changes
Ticker: OTLK · Form: 8-K · Filed: Sep 5, 2025 · CIK: 1649989
| Field | Detail |
|---|---|
| Company | Outlook Therapeutics, Inc. (OTLK) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-changes, filing-update
TL;DR
Outlook Therapeutics moved its HQ to Iselin, NJ and made some board/officer changes.
AI Summary
Outlook Therapeutics, Inc. announced on September 5, 2025, a change in its principal executive offices to 111 S. Wood Avenue, Unit #100, Iselin, New Jersey 08830. This filing also indicates updates regarding the departure of directors, election of directors, appointment of officers, and compensatory arrangements for certain officers.
Why It Matters
A change in principal executive offices can signal operational shifts or strategic realignments within the company. Updates on board and officer changes are crucial for understanding corporate governance and leadership.
Risk Assessment
Risk Level: medium — Changes in executive leadership and board composition can introduce uncertainty regarding future strategy and operational stability.
Key Players & Entities
- Outlook Therapeutics, Inc. (company) — Registrant
- 111 S. Wood Avenue, Unit #100, Iselin, New Jersey 08830 (location) — New Principal Executive Offices
- September 5, 2025 (date) — Date of Report
FAQ
What is the new address for Outlook Therapeutics' principal executive offices?
The new address for Outlook Therapeutics' principal executive offices is 111 S. Wood Avenue, Unit #100, Iselin, New Jersey 08830.
What is the date of this Form 8-K filing?
The date of this Form 8-K filing is September 5, 2025.
What are the main items reported in this 8-K filing?
This 8-K filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What was Outlook Therapeutics' former company name?
Outlook Therapeutics, Inc.'s former company name was Oncobiologics, Inc.
When did the company name change from Oncobiologics, Inc.?
The date of the name change from Oncobiologics, Inc. was August 4, 2015.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2025-09-05 17:00:49
Filing Documents
- tm2525276d1_8k.htm (8-K) — 23KB
- 0001104659-25-087886.txt ( ) — 185KB
- otlk-20250905.xsd (EX-101.SCH) — 3KB
- otlk-20250905_lab.xml (EX-101.LAB) — 33KB
- otlk-20250905_pre.xml (EX-101.PRE) — 22KB
- tm2525276d1_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Commercial Officer On September 5, 2025, Mr. Jeff Evanson stepped down as the Chief Commercial Officer of Outlook Therapeutics, Inc. (the "Company"), effective immediately (the "Effective Date"). Mr. Evanson's departure constitutes a termination of employment without "cause" for purposes of any employment, equity compensation or benefit agreement, plan or arrangement of the Company and its subsidiaries to which Mr. Evanson is a party or otherwise participates, including that certain executive employment agreement, dated as of December 21, 2021, by and between Mr. Evanson and the Company (the "Employment Agreement"). Accordingly, Mr. Evanson will receive severance benefits consistent with the Employment Agreement for a termination of employment without "cause." A description of Mr. Evanson's severance benefits is set forth in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on February 10, 2025, and is incorporated by reference herein.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Outlook Therapeutics, Inc. Date: September 5, 2025 By: /s/ Lawrence A. Kenyon Lawrence A. Kenyon Interim Chief Executive Officer